Actinium Pharmaceuticals, Inc. — fact timeline

Actinium Pharmaceuticals, Inc. received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)(ii), 1003(a)(iii)).

“May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company reported stockholders’ equity of approximately”

Actinium Pharmaceuticals, Inc. engaged CBIZ CPAs P.C. as its auditor.

“On May 08, 2025, with the approval of the Company’s Audit Committee, CBIZ CPAs was engaged as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.”

Actinium Pharmaceuticals, Inc. dismissed Marcum LLP as its auditor.

“(a) Resignation of Independent Registered Public Accounting Firm Based on information provided by Marcum LLP (“ Marcum ”), on November 1, 2024, CBIZ CPAs P.C. (“ CBIZ CPAs ”) acquired the attest business of Marcum. On May 08, 2025, Actinium Pharmaceuticals, Inc. (the “ Company ”) dismissed Marcum as the Company’s independent registered public”

June Almenoff was appointed as Director at Actinium Pharmaceuticals, Inc..

“On November 1, 2024, June Almenoff, M.D., Ph.D., was appointed as a director of Actinium Pharmaceuticals, Inc. (the “Company”)”

Actinium Pharmaceuticals, Inc. shareholders approved Ratification of appointment of Marcum LLP as independent registered public accounting firm for fiscal year ending December 31, 2023.

“For Against Abstain Broker Non-Votes 15,842,146 372,774 280,545 N/A”

Actinium Pharmaceuticals, Inc. shareholders approved Election of David Nicholson and Richard I. Steinhart as Class I directors.

“Director For Withhold Broker Non-Votes David Nicholson 3,959,659 3,275,844 9,087,835 Richard I. Steinhart 5,630,379 1,777,251 9,087,835”

Actinium Pharmaceuticals, Inc. shareholders approved Approve non-binding advisory vote on executive compensation.

“(4) To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers: For Against Withheld /Abstained Broker Non-Votes 9,832,125 2,559,430 387,341 4,892,640”

Actinium Pharmaceuticals, Inc. shareholders approved Ratify appointment of Marcum LLP as independent auditor at the 2022-12-31 meeting.

“(3) To ratify the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022: For Against Withheld /Abstained Broker Non-Votes 16,368,122 913,738 389,676 0”

Actinium Pharmaceuticals, Inc. shareholders approved Approve amendment to 2019 Plan to increase authorized shares.

“(2) To approve an amendment to the Actinium Pharmaceuticals, Inc. 2019 Plan to increase the total number of shares of common stock authorized for issuance under such plan from 5,833,333 by 3,500,000, to a total of 9,333,333 shares to attract and retain the best available personnel and to support planned hiring efforts as the Company grows: For Against Withheld /Abstained Broker Non-Votes 8,780,109 8,533,767 103,453 4,892,640”

Actinium Pharmaceuticals, Inc. shareholders approved Elect Ajit S. Shetty as Class III director.

“(1) To elect Ajit S. Shetty as a Class III director to serve for a three-year term that expires at the 2025 Annual Meeting of Stockholders, or until his successor is elected and qualified or until his earlier resignation or removal: Director For Against Broker Non-Votes Ajit S. Shetty 9,814,712 2,964,185 4,892,640”